WO2001090382A2 - Proteines de fusion agissant en tant que fas-ligand - Google Patents
Proteines de fusion agissant en tant que fas-ligand Download PDFInfo
- Publication number
- WO2001090382A2 WO2001090382A2 PCT/JP2001/004456 JP0104456W WO0190382A2 WO 2001090382 A2 WO2001090382 A2 WO 2001090382A2 JP 0104456 W JP0104456 W JP 0104456W WO 0190382 A2 WO0190382 A2 WO 0190382A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- peptide
- protein
- amino acid
- acid sequence
- fusion protein
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 47
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 44
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 111
- 150000001413 amino acids Chemical group 0.000 claims abstract description 85
- 238000000034 method Methods 0.000 claims abstract description 67
- 108050002568 Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 claims abstract description 51
- 102100031988 Tumor necrosis factor ligand superfamily member 6 Human genes 0.000 claims abstract description 51
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims abstract description 42
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims abstract description 41
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 41
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 41
- 230000004071 biological effect Effects 0.000 claims abstract description 36
- 108091005703 transmembrane proteins Proteins 0.000 claims abstract description 26
- 102000035160 transmembrane proteins Human genes 0.000 claims abstract description 26
- 230000027455 binding Effects 0.000 claims abstract description 16
- 102000037865 fusion proteins Human genes 0.000 claims description 110
- 108020001507 fusion proteins Proteins 0.000 claims description 110
- 230000000694 effects Effects 0.000 claims description 46
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 claims description 44
- 101150064015 FAS gene Proteins 0.000 claims description 44
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 claims description 44
- 230000001965 increasing effect Effects 0.000 claims description 41
- 230000006907 apoptotic process Effects 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 37
- 230000001939 inductive effect Effects 0.000 claims description 24
- 239000013604 expression vector Substances 0.000 claims description 23
- 239000002773 nucleotide Substances 0.000 claims description 21
- 125000003729 nucleotide group Chemical group 0.000 claims description 21
- 108010076504 Protein Sorting Signals Proteins 0.000 claims description 20
- 239000012634 fragment Substances 0.000 claims description 19
- 230000014509 gene expression Effects 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- JUJBNYBVVQSIOU-UHFFFAOYSA-M sodium;4-[2-(4-iodophenyl)-3-(4-nitrophenyl)tetrazol-2-ium-5-yl]benzene-1,3-disulfonate Chemical compound [Na+].C1=CC([N+](=O)[O-])=CC=C1N1[N+](C=2C=CC(I)=CC=2)=NC(C=2C(=CC(=CC=2)S([O-])(=O)=O)S([O-])(=O)=O)=N1 JUJBNYBVVQSIOU-UHFFFAOYSA-M 0.000 claims description 9
- 238000003556 assay Methods 0.000 claims description 8
- 230000003833 cell viability Effects 0.000 claims description 5
- 238000012258 culturing Methods 0.000 claims description 4
- 230000004927 fusion Effects 0.000 claims description 4
- 125000001909 leucine group Chemical group [H]N(*)C(C(*)=O)C([H])([H])C(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 4
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 3
- LHSGPCFBGJHPCY-UHFFFAOYSA-N L-leucine-L-tyrosine Natural products CC(C)CC(N)C(=O)NC(C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-UHFFFAOYSA-N 0.000 claims description 2
- LHSGPCFBGJHPCY-STQMWFEESA-N Leu-Tyr Chemical compound CC(C)C[C@H](N)C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 LHSGPCFBGJHPCY-STQMWFEESA-N 0.000 claims description 2
- AOLHUMAVONBBEZ-STQMWFEESA-N Tyr-Lys Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@@H](N)CC1=CC=C(O)C=C1 AOLHUMAVONBBEZ-STQMWFEESA-N 0.000 claims description 2
- 108010012058 leucyltyrosine Proteins 0.000 claims description 2
- 108010051110 tyrosyl-lysine Proteins 0.000 claims description 2
- 210000004885 white matter Anatomy 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 22
- 230000003028 elevating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 57
- 108020004414 DNA Proteins 0.000 description 32
- 235000018102 proteins Nutrition 0.000 description 29
- 101000638161 Homo sapiens Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 26
- 235000001014 amino acid Nutrition 0.000 description 23
- 229940024606 amino acid Drugs 0.000 description 22
- 230000000692 anti-sense effect Effects 0.000 description 22
- 239000003446 ligand Substances 0.000 description 21
- XZWYTXMRWQJBGX-VXBMVYAYSA-N FLAG peptide Chemical compound NCCCC[C@@H](C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@@H](N)CC(O)=O)CC1=CC=C(O)C=C1 XZWYTXMRWQJBGX-VXBMVYAYSA-N 0.000 description 20
- 108010020195 FLAG peptide Proteins 0.000 description 20
- 241000282414 Homo sapiens Species 0.000 description 18
- 239000013612 plasmid Substances 0.000 description 18
- 239000012228 culture supernatant Substances 0.000 description 13
- 239000000243 solution Substances 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 101100007328 Cocos nucifera COS-1 gene Proteins 0.000 description 9
- 238000006467 substitution reaction Methods 0.000 description 9
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- 241000588724 Escherichia coli Species 0.000 description 6
- 238000007792 addition Methods 0.000 description 6
- 238000012217 deletion Methods 0.000 description 6
- 230000037430 deletion Effects 0.000 description 6
- 230000002829 reductive effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 229920002307 Dextran Polymers 0.000 description 5
- 102100040247 Tumor necrosis factor Human genes 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 238000010353 genetic engineering Methods 0.000 description 5
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 229960000310 isoleucine Drugs 0.000 description 4
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- 208000002109 Argyria Diseases 0.000 description 3
- 108010029697 CD40 Ligand Proteins 0.000 description 3
- 102100032937 CD40 ligand Human genes 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 101000638240 Mus musculus Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 3
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 3
- 101000638260 Rattus norvegicus Tumor necrosis factor ligand superfamily member 6 Proteins 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 3
- 210000001744 T-lymphocyte Anatomy 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 238000001042 affinity chromatography Methods 0.000 description 3
- 210000004899 c-terminal region Anatomy 0.000 description 3
- 239000000539 dimer Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000001962 electrophoresis Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000007429 general method Methods 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 239000012264 purified product Substances 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 230000003248 secreting effect Effects 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 230000014616 translation Effects 0.000 description 3
- 239000013638 trimer Substances 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 102100026398 Cyclic AMP-responsive element-binding protein 3 Human genes 0.000 description 2
- 102100029727 Enteropeptidase Human genes 0.000 description 2
- 108010013369 Enteropeptidase Proteins 0.000 description 2
- 241001481760 Erethizon dorsatum Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000238631 Hexapoda Species 0.000 description 2
- 108010033040 Histones Proteins 0.000 description 2
- 101000855520 Homo sapiens Cyclic AMP-responsive element-binding protein 3 Proteins 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 241000555745 Sciuridae Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 2
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 235000013330 chicken meat Nutrition 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 230000031146 intracellular signal transduction Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 210000001236 prokaryotic cell Anatomy 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 229940126585 therapeutic drug Drugs 0.000 description 2
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 2
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- PLVPPLCLBIEYEA-AATRIKPKSA-N (E)-3-(indol-3-yl)acrylic acid Chemical compound C1=CC=C2C(/C=C/C(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-AATRIKPKSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 108010025188 Alcohol oxidase Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 244000063299 Bacillus subtilis Species 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000700199 Cavia porcellus Species 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- 102000005927 Cysteine Proteases Human genes 0.000 description 1
- 108010005843 Cysteine Proteases Proteins 0.000 description 1
- 101150074155 DHFR gene Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 101710088194 Dehydrogenase Proteins 0.000 description 1
- 102100024746 Dihydrofolate reductase Human genes 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 1
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 1
- 102100031547 HLA class II histocompatibility antigen, DO alpha chain Human genes 0.000 description 1
- 102100034523 Histone H4 Human genes 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 101000866278 Homo sapiens HLA class II histocompatibility antigen, DO alpha chain Proteins 0.000 description 1
- 101100369992 Homo sapiens TNFSF10 gene Proteins 0.000 description 1
- 101000610605 Homo sapiens Tumor necrosis factor receptor superfamily member 10A Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 108700001097 Insect Genes Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 101710141347 Major envelope glycoprotein Proteins 0.000 description 1
- 208000001940 Massive Hepatic Necrosis Diseases 0.000 description 1
- 108700005443 Microbial Genes Proteins 0.000 description 1
- 102000016943 Muramidase Human genes 0.000 description 1
- 108010014251 Muramidase Proteins 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 101100537545 Mus musculus Fas gene Proteins 0.000 description 1
- 102100025243 Myeloid cell surface antigen CD33 Human genes 0.000 description 1
- 108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 1
- 241001181114 Neta Species 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 1
- 102000004211 Platelet factor 4 Human genes 0.000 description 1
- 108090000778 Platelet factor 4 Proteins 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 108020005091 Replication Origin Proteins 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 102000046283 TNF-Related Apoptosis-Inducing Ligand Human genes 0.000 description 1
- 108700012411 TNFSF10 Proteins 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 108091005906 Type I transmembrane proteins Proteins 0.000 description 1
- 108700005077 Viral Genes Proteins 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000004671 cell-free system Anatomy 0.000 description 1
- 239000004568 cement Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000011098 chromatofocusing Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 108010057085 cytokine receptors Proteins 0.000 description 1
- 102000003675 cytokine receptors Human genes 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- SUYVUBYJARFZHO-RRKCRQDMSA-N dATP Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-RRKCRQDMSA-N 0.000 description 1
- SUYVUBYJARFZHO-UHFFFAOYSA-N dATP Natural products C1=NC=2C(N)=NC=NC=2N1C1CC(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 SUYVUBYJARFZHO-UHFFFAOYSA-N 0.000 description 1
- RGWHQCVHVJXOKC-SHYZEUOFSA-J dCTP(4-) Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)C1 RGWHQCVHVJXOKC-SHYZEUOFSA-J 0.000 description 1
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 108020001096 dihydrofolate reductase Proteins 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- -1 for example Chemical class 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- PLVPPLCLBIEYEA-UHFFFAOYSA-N indoleacrylic acid Natural products C1=CC=C2C(C=CC(=O)O)=CNC2=C1 PLVPPLCLBIEYEA-UHFFFAOYSA-N 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 210000005229 liver cell Anatomy 0.000 description 1
- 229960000274 lysozyme Drugs 0.000 description 1
- 239000004325 lysozyme Substances 0.000 description 1
- 235000010335 lysozyme Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- 238000000520 microinjection Methods 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 210000001322 periplasm Anatomy 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 210000001938 protoplast Anatomy 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 238000005185 salting out Methods 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a fusion protein having a biological activity as a Fs ligand, a DNA encoding the same, an expression vector containing the DNA, and a cell transformed with the vector.
- the present invention also provides a method for increasing the production amount of a recombinant protein which is useful for the production of the fusion protein, and which can be applied to all recombinant proteins. It provides a method for increasing biological activity.
- Fas is a type I transmembrane protein with a molecular weight of about 45 kD that belongs to the TNF receptor Yuichi family and has anti-Fas antibody (Yone ha raeta 1., J. Ex P. Med. 169: 1747, 1989) ) And APO-1 antibody (Trautheta 1., Science 267: 1456, 1989) and are cell surface antigens that transmit apoptotic signals to cells.
- Human Fas ligand is a type II transmembrane with a molecular weight of about 40 kD, belonging to the TNF family, which was first reported by Nagata et al. As a biological molecule that induces apoptosis in cells expressing Fas. Type protein (Tak ah ashieta 1., Inte rn ati ona l I mm uno 1 ogy 6: 1567, 1994) and, like TNF, are thought to form trimers in vivo (Tanakaeta 1., EMBO J. 14: 1129, 1995). In addition, rat Fas ligand (Sudaeta 1.
- Fas intracellular signal transduction mechanism of apoptosis via Fas
- Fas the intracellular region of Fas
- a death domain a region called the death domain (Death doma in)
- Caspases a series of cysteine proteases contribute to the signaling of apoptosis via Fas.
- Fas-mediated apoptosis is associated with various diseases and physiological phenomena.
- abnormalities of Fas-mediated apoptosis may be involved in liver cell death in viral fulminant hepatitis and certain autoimmune diseases.
- the Fas-Fas ligand system may be responsible for functions other than apoptosis, such as the action on neutrophils and inflammatory activity (Karagaki et al. Immunity 28: 667, 1996).
- expressing a biologically active recombinant protein having appropriate tertiary and quaternary structures using transformants is often an important issue.
- transmembrane proteins as soluble proteins with biological activity. Soluble proteins are useful in applications to pharmaceuticals that require large amounts of highly purified proteins.
- Soluble forms of the transmembrane protein have been prepared by removing the transmembrane and cytoplasmic domains and adding an appropriate signal peptide to allow secretion of the soluble form of the protein (Smithhet). 'a 1., Science 238: 1704, 1987; Treigereta 1., J. Immunol. 136: 4099, 1986).
- Fas ligand a fusion protein of the CD8 signal sequence and its extracellular domain with a human Fas ligand extracellular domain has been disclosed (US Pat. No. 6,001,962).
- Fas ligand has a lower biological activity than a full-length form of a Fas ligand, and has a high activity that can be used in the pharmaceutical field. No provision of a Fas ligand has been made so far. As with the Fas ligand, trimer formation is considered to be important for activity.
- CD40 ligand a member of the TNF family, use a leucine zipper to prepare a trimeric CD40 ligand. A method has been disclosed (U.S. Pat. No. 5,716,805).
- the fusion protein contains a peptide having an oligomer-forming ability such as leucine zipper, the yield of a soluble protein having a retained function may be significantly reduced, and it may be difficult to secure the production amount.
- FLAG-like peptides do not alter the biological activity of the fusion protein and provide an epitope that is recognized by a specific monoclonal antibody, which allows for rapid detection and easy purification of the expressed fusion protein. Becomes possible.
- FLAG-like peptides have been used only as tags for purification.
- An object of the present invention is to provide a large amount of a Fs ligand fusion protein having high biological activity in a simple and convenient manner. Also provided are a method for simply increasing the amount of recombinant protein produced and a method for increasing the biological activity of a fusion protein of leucine zipper and transmembrane protein, which can be used for that purpose.
- the convenient and large-scale supply of a Fs ligand fusion protein having high biological activity will lead to the development of a therapeutic drug for a disease involving Fap-mediated apoptosis. It is also essential for elucidation of intracellular signal transduction pathways triggered by binding of Fasâ; Fas ligands, and searching for new factors that control the interaction of FasâFas ligands. Is expected in the field.
- the present inventor has conducted intensive studies to obtain a high production amount of a Fs ligand having high biological activity. As a result, we succeeded in obtaining highly active and high-yield Fass ligands by using them as fusion proteins with leucine zippers and FLAG-like peptides.
- a FLAG-like peptide has an effect of increasing the production amount of a recombinant protein and an effect of increasing the biological activity of a fusion protein of leucine zipper and a transmembrane protein.
- the first aspect of the present invention comprises a peptide having at least a part of the amino acid sequence of a Fas ligand, a peptide capable of forming an oligomer, and a peptide capable of increasing the amount of recombinant protein produced, and binds to Fas. Is a fusion protein.
- a second aspect of the present invention is a DNA having a nucleotide sequence encoding the fusion protein of the first aspect of the present invention.
- a third aspect of the present invention is an expression vector comprising the DNA of the second aspect of the present invention.
- a fourth aspect of the present invention is a transformant transformed with the expression vector of the third aspect of the present invention.
- a fifth aspect of the present invention is a method for increasing the amount of recombinant protein produced, comprising producing a desired protein as a fusion protein with a FLAG-like peptide.
- an expression vector containing a DNA fragment in which a nucleotide sequence encoding a desired protein and a nucleotide sequence encoding a FLAG-like peptide are ligated in reading frame to prepare a host and a host
- the expression vector is introduced into appropriate cells or microorganisms, and the resulting transformant is cultured under conditions suitable for expression.
- a method for producing a recombinant protein which comprises a step of recovering and purifying and increasing the production amount of the desired protein.
- a seventh aspect of the present invention is a method for increasing the biological activity of a leucine zipper and a transmembrane protein by preparing a fusion protein of the fusion protein and further linking a FLAG-like peptide to the fusion protein. It is. BRIEF DESCRIPTION OF THE FIGURES
- FIG. 1 is a graph showing apoptosis-inducing activity of various Fs ligand fusion proteins on Jurkat cells.
- FIG. 2 is a diagram schematically illustrating the primary structures of various human Fass ligand fusion proteins.
- FIG. 3 is a diagram in which purified FLAG-I1eZip-shFasL was subjected to silver staining after electrophoresis.
- a Fas ligand is a substance having an activity of binding to Fas at least as its biological activity. More preferably, it is a substance having an activity of inducing apoptosis in cells expressing Fas. That is, in the description herein, the biological activity relating to the Fas ligand refers to the activity of binding to Fas, and more preferably the activity of inducing apoptosis in cells expressing Fas. I do.
- Fas or Fas ligand as used herein is derived from any animal species such as, for example, human, mouse, rat, guinea pig, chicken, porcupine, pig, sheep, wedge, porcupine, porcine, monkey, cat, dog, marmot However, it is preferably of human origin.
- the (a) peptide having at least a part of the amino acid sequence of the Fas ligand according to the first embodiment of the present invention is preferably a peptide having the entire amino acid sequence of SEQ ID NO: 1 in the sequence listing, and A peptide having an arbitrary part of an amino acid sequence having an arbitrary length and having a biological activity as a Fas ligand.
- the amino acid sequence is defined by adding one or more amino acids such as met to one or both of the N-terminus and the C-terminus or both. Peptide, or one or more amino acid mutations, additions, deletions, or substitutions at any position in the amino acid sequence as long as they have the biological activity of a Fas ligand.
- the amino acid sequence of rat or mouse Fas ligand can be positioned as having multiple substitutions or deletions in the amino acid sequence of human Fas ligand. It is known to have active activity. Similarly, rhesus monkeys (Wangeta 1. Human Immunology 59: 599, 1998) and other animals such as guinea pigs, chickens, rabbits, pigs, hidges, horses, pests, monkeys, cats, dogs, marmots, etc. Even if the species-derived Fas ligand has a biological activity as a Fas ligand, the amino acid sequence of the Fas ligand of the first embodiment of the present invention may be reduced. Are included in peptides having a part.
- a peptide having at least a portion of the amino acid sequence of a Fas ligand is the extracellular domain of a Fas ligand.
- the extracellular domain of the Fas ligand corresponds to the 103-281 amino acid portion of the human Fas ligand described in SEQ ID NO: 1 in the sequence listing.
- Another preferred example is a 130 to 281 amino acid portion corresponding to a soluble human Fas ligand which is released from a membrane-type human Fas ligand in vivo by protease cleavage.
- the fusion protein of the first embodiment of the present invention may or may not have an activity of inducing apoptosis as long as it has an activity of binding to Fas.
- the fusion protein of the first aspect of the present invention preferably has an activity of inducing apoptosis. It is known that a human Fas ligand requires an amino acid portion of 145 to 281 amino acids from the N-terminus for apoptosis-inducing activity. Accordingly, the fusion protein of the first embodiment of the present invention preferably contains the amino acid sequence of the Fas ligand, which contains at least a part of the amino acid sequence of human Fas ligand, which is 145 to 281 amino acids. However, those having a stronger apoptosis-inducing activity are preferably those containing a sequence corresponding to the amino acid sequence of the 144th and subsequent amino acids of human Fas ligand.
- a peptide capable of forming an oligomer is a peptide capable of self-associating into a dimer, a trimer, or a higher oligomer, and in many cases, an â -helix or / 3âCan have a secondary structure like a sheet. Roy; one is provided as a suitable example.
- Leucine zipper is a term used to refer to a repetitive seven residue motif denoted as (ab cdefg) n (where n is 4 or 5) that exists as a conserved domain in many proteins.
- a and d are generally hydrophobic residues such as leucine or isoleucine, which are aligned on the same side of the helix (McLa chal an et al., J. MoI. Biol. l. 98: 293, 1975).
- the leucine residue at position d contributes to a large hydrophobic stabilizing energy and is important for dimer formation (Kry steketal., Int. J. Peptide Rep. s. 38: 229, 19,91).
- amino acid substitutions corresponding to the above formula a and d residues of leucine zippers alter the oligomer-forming properties of leucine zippers (Harburyetal., Science 262: 1401, 1993.).
- leucine zipper will still form a parallel dimer.
- the leucine residues at position d replace isoloidin, the resulting peptide will spontaneously form a trimeric parallel helical coil in solution.
- Substitution of all amino acids at position d with isoleucine and all amino acids at position a with leucine forms a tetramer.
- peptides containing these substitutions are still referred to as leucine zippers.
- a most preferred example of the leucine zipper has a sequence shown in SEQ ID NO: 2, but is not limited thereto as long as it has an oligomer-forming ability.
- peptides capable of forming oligomers include sequences involved in p53 tetramerization, platelet factor 4, and partial sequences of histone H3 and H4 proteins. (These are described in detail in Japanese Patent Publication No. 11-508126, which is incorporated herein by reference.)
- mutations, additions, deletions, and substitutions of one or more amino acids at any position in the amino acid sequence are included in the leucine zipper as long as they have biological activity. It is.
- Peptides that increase the amount of recombinant protein produced include, for example, the effect of increasing the amount of fusion protein that can be recovered from the culture supernatant when producing the fusion protein in mammalian cells, and the production of the fusion protein in E. coli. It means a peptide that has the effect of increasing the amount of fusion protein that can be recovered from the lysate of the bacterial cells during the culturing.
- the present inventors have found FLAG-like peptides for the first time as a preferred example of a peptide that increases the production of a recombinant protein.
- the FLAG-like peptide is preferably a FLAG peptide consisting of 8 amino acids of As-Tyr-Lys-Asp-Asp-Asp-Lys.
- any amino acid sequence can be used as long as it has the effect of increasing the amount of recombinant protein produced, more preferably the effect of increasing the biological activity of the fusion protein of leucine zipper and the transmembrane protein.
- Such a peptide is called a FLAG-like peptide.
- a spâL euâTy r One peptide having an amino acid sequence of AspâAspâAspâAspâLys is also used as having the same function as the above-mentioned sequence consisting of 8 amino acids.
- the amino acid sequence is AspâBâZâAspâAspâAs â âAspâLys ( â , TyrâLys or LeuâTyr).
- A) can be represented as a peptide consisting of As another form, as described in JP-B-7-4255, the amino acid sequence is As â -Tyr-Lys- Xn -R (where R is Lys, Arg, Met or Asn, and Xi- n means any amino acid other than Lys, Arg, Met and Asn.
- n is not particularly limited, but is preferably 3 to 5.
- the fusion protein of the present invention is composed of a peptide having at least a part of the amino acid sequence of the Fas ligand, a peptide capable of forming an oligomer, and a peptide capable of increasing the production amount of the recombinant protein. As long as it retains the activity of inducing apoptosis in cells expressing Fas.
- the three peptides can be linked in any order. It may contain any linker sequence or signal sequence.
- Fas ligand In the case of Fas ligand, it is known that it interacts with Fas at the C-terminal side, so that peptides having oligomer-forming ability and peptides that increase the amount of recombinant protein produced must be at least the amino acid sequence of the Fas ligand. It is preferable to be linked to the N-terminal side of the peptide having a part. Linker sequences are well known in the art. Examples of signal sequences include mouse T lymphocyte antigen CD8 signal sequence, baculovirus gp67 protein signal sequence, and GâCSF signal. And a signal sequence that promotes secretion of a protein such as the human Fas signal sequence.
- a preferred example of the fusion protein of the present invention is a fusion protein in which a FLAG-like peptide, a leucine zipper, and an extracellular domain of a human Fs ligand are linked in this order from the N-terminal side.
- the most preferred example has the amino acid sequence shown in SEQ ID NO: 4 in the sequence listing, and is linked from the N-terminal side in the order of human Fas signal sequence, FLAG peptide, leucine zipper, extracellular domain of human Fas ligand The fused 'protein.
- an amino acid sequence obtained by adding one or more amino acids such as Met to one or both of the N-terminus and the C-terminus, or both. Mutants, additions, deletions, or substitutions of one or more amino acids at any position in the defined peptide or amino acid sequence are included in the fusion protein of the present invention.
- WST-1 Atsushi can be performed according to Takara Shuzo's Premix WST-1 Cell P roliferati on Assay System.
- Fas-expressing cells it is preferable to use Jurkat cells, which are cell lines derived from human T cells.
- an assay other than WST-1 assay for example, in order to examine the ability to bind to Fas, a method of performing immunoprecipitation between Fas and the fusion protein of the present invention, or a method of fluorescently labeling an antibody that recognizes the fusion protein, was used. Then, the fusion protein bound to the cells expressing Fas can be examined by flow cytometry. Also induces apoptosis The activity can be assayed by a method such as Rubies (J. Exp. Med. 177: 195, 1993).
- the apoptosis-inducing activity of the fusion protein of the present invention is preferably such that the cell viability when adding 3 ng / mL of the fusion protein to WST-1 assay shown in the Examples is 50% or less. It can be evaluated that the lower the cell viability in the same assay, the higher the apoptosis-inducing activity of the fusion protein.
- the fusion protein of the present invention which has a high apoptosis-inducing activity, is useful when applied to pharmaceuticals, because it can reduce the therapeutically effective dose, thereby reducing side effects and reducing production costs.
- a more preferred example of the fusion protein of the present invention has an apoptosis-inducing activity in which the cell viability achieved when the fusion protein is added at 3 ng / mL is 20% or less in the same assay.
- the fusion protein of the present invention is characterized in that by using both a FLAG-like peptide and a leucine zipper, the activity as a Fas ligand is increased and the amount of fusion protein produced is also increased. In the case of molecules such as Fas ligand that can form a multimeric structure in vivo, it was predictable that a fusion protein with leucine zipper would be able to obtain an active recombinant protein.
- the fusion protein of the present invention has a production amount of at least 1.5 times or more, preferably 2 times or more, more preferably 3 times or more, and more preferably, as compared with the case of using a fusion protein with leucine zipper alone.
- the biological activity as a Fas ligand is 1.5 times or more, preferably 2 times or more, more preferably 3 times or more, and further preferably 5 times or more.
- especially preferred The feature is that it is 10 times or more.
- the fusion protein of the first embodiment of the present invention is produced as a recombinant protein by genetic engineering.
- Examples of producing the fusion protein by genetic engineering include transforming an appropriate host cell using the novel DNA of the second embodiment of the present invention described later or the expression vector of the third embodiment, The obtained transformant is cultured to recover a culture mixture, and the fusion protein is purified.
- a method for synthesizing a cell-free system using the DNA or the recombinant DNA molecule (Sambrook eta. 1. Molecular Cloning 2 nded. Cold Spring Harbor Laboratory, New York (1989) is also one of the methods for production by genetic engineering.
- a preferred method for producing a fusion protein by genetic engineering will be described in the sixth embodiment of the present invention.
- the DNA has a nucleotide sequence encoding the fusion protein of the first aspect of the present invention. Since the fusion protein is composed of a peptide having at least a part of the amino acid sequence of Fas ligand, a peptide capable of forming an oligomer, and a peptide capable of increasing the amount of recombinant protein produced, the DNA It is a sequence obtained by linking nucleotide sequences encoding various kinds of peptides with their reading frames aligned.
- the nucleotide sequences encoding the three peptides may be linked in any order, and may include an arbitrary linker sequence or a nucleotide sequence encoding a signal sequence.
- Fas ligand it is known that it interacts with Fas on the C-terminal side.
- the nucleotide sequence encoding a peptide capable of forming oligomers and a peptide capable of increasing the amount of recombinant protein produced is a nucleotide sequence encoding a peptide having at least a part of the amino acid sequence of the Fas ligand. It is preferably linked to the 5 'end of the amino acid.
- DNAs for polypeptides having the same function are homologous to each other and often hybridize to each other even if the animal species or individual is different.
- the diversity of amino acids also often occurs to the extent that the DNAs that encode them hybridize to each other.
- DNA cloning by the hybridization method indicates that DNAs encoding different amino acid sequences hybridize to each other.
- Polypeptides having amino acid sequences encoded by DNAs that hybridize to one another are considered to have substantially the same function.
- the fusion protein of the present invention contains an amino acid sequence encoded by a nucleotide sequence that hybridizes to a nucleotide sequence complementary to the nucleotide sequence encoding the amino acid sequence, and has an activity of binding to Fas. Can also be characterized. '
- the DNA fragment having a nucleotide sequence encoding each of the three peptides may be obtained by any method. That is, it may be chemically synthesized or cloned from an appropriate DNA library. Alternatively, it may be prepared by excision from another recombinant DNA having the sequence by treatment with a restriction enzyme, or another recombinant DNA may be used as a â type and subjected to a PCR method using an appropriate primer. It may be prepared by amplification. Those DNA fragments are public The fragments may be joined by the known ligation method, or the mixture of fragments may be converted into a continuous DNA fragment by the PCR method using an appropriate primer with a type III mixture.
- the expression vector of the third aspect of the present invention contains the above-described DNA of the second aspect of the present invention.
- This DNA fragment is operably linked to appropriate transcriptional and Z- or translation-regulating sequences, such as those obtained from mammalian, microbial, viral, or insect genes.
- regulatory sequences include sequences having a regulatory role in gene expression (eg, transcription motors or enhancers), operator sequences to control transcription, sequences encoding mRNA ribosome binding sites, polyadenylation sites, Includes splice donor and acceptor sites, as well as appropriate sequences that control the initiation and termination of transcription and translation. The need for these nucleotide sequences is determined by the intended use of the expression vector.
- the expression vector of the third aspect of the present invention can be obtained by introducing the DNA of the second aspect of the present invention into any vector. If necessary, the DNA may be introduced into an arbitrary vector together with another nucleotide sequence.
- a method for introducing DNA into a vector is known (Sammbook eta l.Molecu lar Cloning 2nd ed. Cold Spring Harbor Laboratory, New York 1989). . That is, DNA and vector are each digested with an appropriate restriction enzyme, and each obtained fragment may be ligated using DNA ligase.
- the vector may be any vector such as a plasmid vector, a phage vector, a virus vector, and the like.
- the expression vector preferably has an E. coli replication origin, a marker gene, and a polyA additional sequence in addition to the DNA of the second embodiment of the present invention.
- those having the promoter of SV40 and the promoter of SR, which function in animal cells, and the promoter of promoter of human celllongation factor 1 (EF1 â ) are also preferred examples of the expression vector.
- the transformant according to the fourth aspect of the present invention is transformed with the expression vector according to the third aspect of the present invention. That is, the transformant of the fourth aspect of the present invention is transformed by directly introducing the expression vector of the third aspect of the present invention into an appropriate host cell or microorganism.
- Methods for introducing the expression vector according to the third aspect of the present invention into host cells include electoporation method, protoplast method, alkali metal method, calcium phosphate precipitation method, DEAE dextran method, microinjection method, and virus particles.
- the transformant of the present invention can also be used for the purpose of producing the DN molecule of the second aspect of the present invention in large quantities.
- the transformant produces the fusion protein of the first aspect of the present invention. Therefore, such a transformant is It can be used for the purpose of producing the fusion protein of the first aspect of the present invention and the like.
- the transformant according to the fourth aspect of the present invention may be either a prokaryotic cell or a eukaryotic cell.
- prokaryotic cells is Escherichia coli Bacillus subtilis.
- eukaryotic cells include mammalian cells such as CHO cells, HeLa cells, COS cells, and Namawa cells, as well as insect cells such as S â cells and yeast.
- the transformant produces the fusion protein of the present invention, and more preferably, secretes the fusion protein of the present invention into the medium.
- One of the most preferred examples is COS-1 cells.
- a fifth embodiment of the present invention a method for increasing the amount of recombinant protein produced, which comprises producing a desired protein as a fusion protein with a FLAG-like peptide, will be described.
- Increasing the amount of recombinant protein produced means, for example, increasing the amount of protein that can be recovered from the culture supernatant when producing the fusion protein in mammalian cells, or increasing the amount of bacterial cells when producing the fusion protein in E. coli. Means that the amount of protein that can be recovered from the lysate increases.
- the FLAG-like peptide is used not only as a tag for purification as in the past but also as a sequence for increasing the amount of recombinant protein produced.
- Conventionally known sequences that increase the amount of recombinant protein produced include secretory signal sequences. Secretory signal peptides facilitate secretion of proteins from cells.
- the present inventors have newly found that the FLAG-like peptide is not a secretory signal sequence, but has an effect of increasing the amount of recombinant protein produced.
- Example 2 when producing the extracellular domain of the Fas ligand in COS-1 cells, the N-terminal side of the extracellular domain of the Fas ligand Ligation of the FLAG peptide resulted in an approximately 3-fold increase in production.
- leucine zipper was ligated to the N-terminal side of the extracellular domain of the Fas ligand to increase biological activity, the expression level was significantly reduced due to the presence of leucine zipper. Ligation increased the production by 20-35 times.
- a problem may occur in that the production amount is significantly reduced.
- the FLAG-like peptide can be further fused to increase the production amount.
- a method for producing a desired protein as a fusion protein with a FLAG-like peptide will be described in the sixth embodiment of the present invention.
- an expression vector containing a DNA fragment in which a nucleotide sequence encoding a desired protein and a nucleotide sequence encoding a FLAG-like peptide are ligated in reading frame and And introducing the expression vector into appropriate cells or microorganisms as hosts, culturing the resulting transformant under conditions suitable for expression, and recovering and purifying the recombinant protein from the culture mixture.
- a method for producing a recombinant protein that increases the production of the desired protein is described.
- the nucleotide sequence encoding the desired protein and the nucleotide sequence encoding the FLAG-like peptide may be ligated in any order as long as the effect of increasing the production amount by the FLAG-like peptide is recognized. And a base sequence encoding a signal sequence.
- the expression vector is described in the third embodiment of the present invention.
- the transformant is described in the fourth embodiment of the present invention.
- the transformant can be cultured by a general method.
- culturing transformants There are various books (âMicrobial Experiment Methodâ, edited by The Biochemical Society of Japan, Tokyo Kagaku Dojin, 1992, etc.), which can be referred to.
- the necessity of a method for gene amplification and expression induction depends on the type of host cell and the promoter used. For example, it can be induced with 3] 3-indoleacrylic acid when the promoter is the trp promoter, with dexamethasone when the MM TV promoter is used, and with methanol when the â 1 promoter is used.
- DHFR farnesolate dehydrogenase
- the culture mixture is a culture supernatant or cells. That is, when the transformant secretes the recombinant protein extracellularly, the protein is recovered and purified using the culture supernatant as a material.
- the recombinant protein accumulates in the host cells, the cells are disrupted using lysozyme, detergent, freeze-thaw, pressurization, etc., and then centrifuged to collect the supernatant. Then, after removing unnecessary cell fragments and the like by filtration or the like, the recombinant protein is purified using the material as a material.
- a method such as virus key (J. B acteriol. 127: 595, 19776) may be used. Can be used.
- a method for purifying the recombinant protein from the culture mixture an appropriate method can be appropriately selected from methods usually used for protein purification. That is, various affinity chromatography such as salting-out method, P-Gori extrafiltration method, isoelectric point precipitation method, gel filtration method, electrophoresis method, ion exchange chromatography, hydrophobic chromatography, antibody chromatography, etc.
- a preferred example is the method described in Example 4.
- Another suitable example includes affinity chromatography using specific antibodies to FLAG-like peptides, the method of which is disclosed in US Pat. No. 5,011,912.
- the FLAG-like peptide containing the amino acid sequence AspâAspâAspâAsp-Lys can be excised using enterokinase, and the recombinant protein is obtained by removing the FLAG-like peptide.
- âincrease in the amount of protein productionâ means that the amount of production is at least 1.5 times or more as compared with the case where the protein is not a fusion protein with a FLAG-like peptide. Means 2 times or more, more preferably 3 times or more, further preferably 20 times or more, particularly preferably 30 times or more.
- an EIA system using an antibody specific to the target protein as shown in Example 2 can be used, or a general method available to those skilled in the art can be used.
- a FLAG-like peptide is fused by further linking a FLAG-like peptide to the fusion protein.
- Leucine zippers have been described in the first aspect of the present invention.
- transmembrane proteins include the TNF family, to which TNF «, Fas ligand, TRAIL, CD40 ligand, etc. belong, and the TNFZNGF receptor, to which TNF receptor, Fas, DR4, etc. belong.
- Transmembrane proteins generally have the function of transmitting signals into cells, but as long as they have the activity of binding both, they have the activity of transmitting signals into cells by binding both. It may or may not have one. When it binds but does not transmit a signal, it can be used to suppress changes in the phenotype of cells in response to the signal. However, it is preferable that they have an activity of transmitting an intracellular signal by binding of the two and inducing a change in the expression system of the cell in response to the signal.
- the fusion protein produced by the method of the seventh aspect of the present invention is composed of a FLAG-like peptide, a mouth isin zipper, and a transmembrane protein, as long as the biological activity of the transmembrane protein is retained.
- the three peptides may be linked in any order, and may include any linker sequence or signal sequence.
- a transmembrane protein is a peptide having an entire amino acid sequence, a peptide having an arbitrary portion of any length of the amino acid sequence, or an amino acid sequence thereof, as long as its biological activity is maintained.
- a mutation, addition, deletion, or substitution of one or more amino acids may occur at any position in the amino acid sequence.
- a preferred example to which the method of the seventh embodiment of the present invention can be applied is a case where the extracellular domain of a Fas ligand is used as a transmembrane protein.
- the fusion protein linked in the order of the FLAG peptide single-mouthed isinzipper and the human Fas ligand extracellular domain was fused to the non-FLAG peptide-linked leucine zipper-human Fas ligand extracellular domain. It had about 10-fold apoptosis-inducing activity as compared to the protein. That is, by linking the FLAG peptide, the biological activity of the fusion protein of leucine zipper and Fas ligand as a Fas ligand was successfully increased.
- âincrease in biological activityâ means that at least one value of the activity or the like is at least large as compared with a case where the protein is not a fusion protein with a FLAG-like peptide. For example, it means 1.5 times or more, preferably 2 times or more, more preferably 3 times or more, further preferably 5 times or more, particularly preferably 10 times or more.
- a general method is used for comparing the activity values and the like, the comparison can be made based on the activity amount per unit amount, that is, the specific activity.
- the specific activity is determined by generally 50% inhibitory concentration (IC 5 Q) or 50% effective dose (ED 5.) And the like.
- Plasmid pMl807 expressing a fusion protein of leucine zipper and human Fs ligand extracellular domain was prepared by the following method.
- antisense primer 4 (AATAAGCTTGGTACCCT ATTAGAGCTTATATAA) were synthesized using a chemical synthesizer.
- This sense primer 11 contains a sequence encoding the human Fas signal sequence.
- Antiserum 1 contains the 3 'terminal region of the sequence encoding the human Fas signal sequence and the 5' terminal region of the sequence encoding the isoleucine zipper.
- Sense Primer 2 contains an intermediate region of the leucine zipper coding sequence.
- Antisense primer 2 contains the 3, terminal region of the leucine zipper coding sequence.
- Sense primer 3 encodes human Fas signal sequence Contains the 5 'end region of the sequence and the EcoRI site (GAATTC).
- Antisense primer 3 contains a nucleotide sequence coding for the 3 'terminal region of the leucine zipper coding sequence, the Pstl site (CTGCAG), and the N-terminal side of the extracellular domain of human Fas ligand.
- Sense primer 14 contains the 3 â² terminal region of the sequence encoding leucine zipper, the PstI site (CTGCAG), and the nucleotide sequence encoding the N-terminal side of the extracellular domain of human Fas ligand.
- Antisense Primer 14 contains a sequence encoding the C-terminal side of the human Fas ligand, a TAA stop codon and a Kpn I site (GGTACC).
- the resulting sense primer 1 and antisense primer 1 or sense primer 2 and antisense primer 2 were each replaced by 50 pmo1, dATP, dCTP, dGTP, and dTTP by 10 nmo1, Pfu DNA polymerase (Stratagene).
- Pfu DNA polymerase (Stratagene).
- Using a DNA thermal cycler (PCR System 9600, PE Biosystems); 30 seconds at 94 ° C; 30 seconds at 55 ° C; 72.
- CCR was performed 30 cycles of PCR with 1 minute as one cycle.
- the resulting PCR products were 0.5 L each, the sense primer 3 and the antisense primer 3 each contained 50 pmo1, each containing 50? # 1
- a reaction solution was prepared and subjected to PCR in the same manner as described above.
- the resulting PCR product was double digested with EcoRI and KpnI.
- the expression plasmid pMl070 International Publication No.WO95 / 13293
- pMl807 which has a sequence encoding the human Fas ligand extracellular domain under the EF promoter and contains the DHFR gene
- pMl807 was double-digested with EcoRI and KpnI.
- a fragment of about 7 kbp was recovered and purified.
- the fragment of the PCR product digested with EcoRI and KpnI described above was incorporated into this vector fragment, and the resulting plasmid was named pMl807.
- Plasmid pMl809 expressing a fusion protein of FLAG peptide and human Fass ligand extracellular domain was prepared by the following method.
- Antisense primer 5 (CTTGTCATCGTCATCCTTGTAG TCAGCAACAGACGTAAGAACC), Sense primer 5 (GAC
- This antisense primer 5 contains 3, the terminal region of the sequence encoding the human Fas signal sequence and the sequence encoding the FLAG peptide.
- Sense primer 5 contains a sequence encoding the FLAG peptide and a nucleotide sequence encoding the N-terminal side of the extracellular domain of human Fas ligand.
- the obtained antisense primer 1 and the sense primer prepared in Example 1 (1) were used.
- a 50-L PCR reaction solution containing 50 pmo1 of each of mer 3 and 0.05 pmo1 of sense primer 11 was prepared, and PCR was carried out in the same manner as in Example 1 (1).
- the sense primer 5 and the antisense primer 14 prepared in Example 1 (1) were used at 50 pmo 1 each, and the â type was used in Example 1 (1).
- a solution was prepared and subjected to PCR similarly. Fifty PCR reaction solutions containing 0.5 L of each of the obtained PCR products and 50 pmo1 of each of the sense primer 3 and the antisense primer 4 were prepared, and PCR was performed in the same manner.
- the PCR product thus obtained was double-digested with EcoRI and KpnI, and incorporated into a vector fragment that was double-digested with EcoRI and KpnI of pMl070 as in Example 1 (1).
- the resulting plasmid was named pMl809.
- Plasmid pUC-I ZFL was prepared by the following method. pUCll8 (Takara Shuzo Co., Ltd.) is digested with PstI, the ends are blunted using DNA Blunting Kit (Takara Shuzo Co., Ltd.), and ligation is performed to crush the PstI site. PUC118 was obtained. This plasmid is double-digested with EcoRI and KpnI, and the PCR product containing the leucine zipper and human Fas ligand extracellular domain prepared in Example 1 (1) is double-digested with EcoRI and KpnI. The obtained plasmid was integrated, and the obtained plasmid was named pUC-I ZFL.
- Plasmid pMl815, which expresses a fusion protein (SEQ ID NO: 4) of FLAG peptide, leucine zipper and human Fas ligand extracellular domain was prepared by the method shown below.
- ATCCTTGTA and Sense Primer-6 (C GATGAC AAGAGAAT GAAAC AAATCGAAGAC) were synthesized using a chemical synthesizer.
- This antisense primer 6 contains the sequence encoding the FLAG peptide and the 5 'end region of the sequence encoding the leucine zipper.
- Sense primer 6 contains the 3 'terminal region of the sequence encoding the FLAG peptide and the 5 terminal region of the sequence encoding leucine zipper.
- Example 1 (1) 5 O â L containing the obtained antisense primer 6 and the sense primer 13 prepared in Example 1 (1) at 50 pmo 1 respectively, and 1 ng of pM1809 prepared in Example 1 (2) as â Was prepared and PCR was performed in the same manner as in Example 1 (1).
- a solution was prepared and subjected to PCR similarly. 0.5 L of each of the obtained PCR products and 50 L of a PCR reaction solution containing 50 pmo1 of each of sense primer 3 and antisense primer 3 were prepared, and PCR was performed in the same manner.
- the PCR product thus obtained was double-digested with EcoRI and PstI.
- the pUC-I ZFL prepared in Example 1 (3) was double-digested with EcoR I and Pst I, and subjected to agarose gel electrophoresis. Collected and refined. The fragment of the PCR product digested with the above EcoRI and PstI was incorporated into this vector side fragment to obtain a plasmid.
- This plasmid was further double-digested with EcoR I and Kpn I, and the EcoR The resulting plasmid was incorporated into a vector-side fragment double-digested with I and Kpn I, and the resulting plasmid was named PM1815.
- the present inventors deposited the plasmid pMl815 with the Patent Organism Depositary, the National Institute of Advanced Industrial Science and Technology at 1-1-1, Higashi, Tsukuba, Ibaraki, Japan on May 12, 2000 (Accession number: FERM P-17853) and transferred from the original deposit to the international deposit on May 8, 2001 (Accession No. FERM BP-7575).
- PMl 815, â 1809, pM1807, and pM1070 (International Publication Number W â 95 / 13293) prepared in Example 1 were introduced into COS-1 cells, and the protein was expressed and secreted in the supernatant. . That is, 1 plasmid was dissolved in 22 10 mM Tris-HCl (pH 7.4) 1 mM ethylenediaminetetraacetic acid solutions. To each of these, add 0.7 mL of D-MEM (Nissui Pharmaceutical Co., Ltd.) containing 0. SmgZmL DEAE-dextran and 50 mM Tris-HCl (pH 7.4), and add the DNA-DEAE-dextran mixture. Produced.
- D-MEM Dissui Pharmaceutical Co., Ltd.
- Fas ligand-specific antibody F 918-20-2 as a solid-phased antibody, F919-9-1-18 as a horseradish peroxidase-labeled antibody.
- EIA Enzymei mmu no ass ay
- WO 97Z02290 International Publication No. WO 97Z02290
- the fusion protein FLAG-shF expressed by the plasmid pMl809 in which the FLAG peptide was fused to the human Fas ligand extracellular domain (shFasL) expressed by pM1070. as L had about three times the production.
- the production amount of I 1 eZip-shFasL (pMl 807) fused with leucine zipper was remarkably reduced, while FLAG_IleZip-sFasL (FLAG peptide-fused) was further reduced.
- M1815 had about 30 times the expression level.
- Example 3 The apoptosis-inducing activity of various Fas ligand fusion proteins by adding the culture supernatant of cells was examined using WST-1 Atsushi shown below.
- the COS-1 cell culture supernatant containing various Fas ligand fusion proteins obtained in Example 2 was diluted to a concentration to be assayed in a 1 â ?] â 11640 medium containing 10% to 83%.
- 50 uLZwe 1 1 become so added previous cell Ueru the implanted 37 ° in C_ â 2 incubator C
- apoptosis-inducing activity was measured.
- 10 â l of WST-1 reagent Premix WST-1 Cell P roliferation Assay System, Takara Shuzo Co., Ltd.
- FLAGâIleZips hFasL showed dose-dependently inhibitory activity on Jurkat cells.
- FLAG-I 1 eZip-shFasL has about 10 times the apoptosis-inducing activity as compared to IleZipshFasL without the fusion of the FLAG peptide.
- FLAG peptide had about 100-fold apoptosis-inducing activity as compared to shFasL to which no fusion was made.
- F919-9-118 details are described in International Publication No. WO 097-0202290
- Fas-F Fas-F It was shown that the activity was specific to the as ligand system.
- an anti-Fas ligand antibody F919-9-18 (International publication) No. WO 097/02290) was purified by affinity chromatography using a Sepharose 4B carrier immobilized as follows. That is, 29,420 mL of COS-1 cell culture supernatant containing FLAGâIleZipâshFasL was passed through a 0.45 m filter (Millipack 60: Millipore), and the filtrate was collected. It was used as a purification starting material.
- the purified starting material was flowed at a flow rate of 10 mL / min onto an F 919-9-9-18-Sepharose 4B FF column ( â 3.2 cm x 6.2 cm) previously equilibrated with phosphate-buffered saline (PBS-) in a cold place. Applied at. After applying the starting materials, the column was flushed with PBS at 15.3 mL / min (washing 1), and then the column was flushed with lmol / L NaCl / PBS- under the same conditions to perform a washing operation (washing 2).
- Table 2 shows the quantitative results. Table 2 F 919-9-18 -Sepharose 4B Sample Volume (mL) FLAG-I Total FLAGâRecovery
- FLAG-I1eZippsFaSL was found only in the eluted fraction.
- Purified FLAG-IleZipsFaSL was obtained at a recovery rate of 84% by F919-9-118-Separose 4B FF column chromatography.
- the purified product was electrophoresed by SDS-PAGE and subjected to silver staining (2D-silver staining reagent â II Daiichi: Daiichi Kagaku), which was detected as a single band (Fig. 3).
- the cytotoxic activity of the purified product was confirmed by the method shown in Example 3. As a result, the purified product showed almost the same activity as the culture supernatant before purification.
- a fusion protein having a biological activity as a Fs ligand is provided.
- the Fas ligand fusion protein provided by the present invention has the effect of increasing the production of oligomer-forming peptides and recombinant proteins and increasing the biological activity of the fusion protein of leucine zipper and transmembrane protein. Since it is a fusion protein with its own peptide, high biological activity and high production are ensured.
- the Fas ligand fusion protein can be developed as a therapeutic drug for a disease involving Fas-mediated apoptosis.
- the present invention also provides a method for increasing the production amount of a recombinant protein which is useful for the production of the fusion protein, and which can be applied to all recombinant proteins. It provides a method for increasing biological activity.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA002410525A CA2410525A1 (en) | 2000-05-26 | 2001-05-28 | Fas ligand-fused proteins |
AU2001260633A AU2001260633A1 (en) | 2000-05-26 | 2001-05-28 | Fas ligand-fused proteins |
US10/296,718 US20040053249A1 (en) | 2000-05-26 | 2001-05-28 | Fas ligand-fused proteins |
JP2001586578A JPWO2001090382A1 (ja) | 2000-05-26 | 2001-05-28 | ïœïœãªã¬ã³ãèåèçœè³ª |
EP01934373A EP1365027A4 (en) | 2000-05-26 | 2001-05-28 | FUSION PROTEINS AS FAS-LIGAND |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2000-156209 | 2000-05-26 | ||
JP2000156209 | 2000-05-26 |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2001090382A2 true WO2001090382A2 (fr) | 2001-11-29 |
WO2001090382A1 WO2001090382A1 (en) | 2001-11-29 |
WO2001090382A3 WO2001090382A3 (fr) | 2003-09-12 |
Family
ID=
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005012363A1 (ja) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | æšçåãããççæ¹èµ·å€ |
JPWO2004022599A1 (ja) * | 2002-08-22 | 2005-12-22 | æ ªåŒäŒç€Ÿããã¿ã€ãã㢠| èåæäœåã³ãã®äœææ¹æ³ |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040918A2 (en) * | 1995-06-07 | 1996-12-19 | Immunex Corporation | Novel cd40l mutein |
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996040918A2 (en) * | 1995-06-07 | 1996-12-19 | Immunex Corporation | Novel cd40l mutein |
Non-Patent Citations (2)
Title |
---|
SARA M. MARIANI ET AL.: 'Expression of biologically active mouse and human CD95/APO-1/Fas ligand in the baculovirus system' JOURNAL OF IMMUNOLOGICAL METHODS vol. 193, 1996, pages 63 - 70, XP002945441 * |
See also references of EP1365027A2 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2004022599A1 (ja) * | 2002-08-22 | 2005-12-22 | æ ªåŒäŒç€Ÿããã¿ã€ãã㢠| èåæäœåã³ãã®äœææ¹æ³ |
WO2005012363A1 (ja) * | 2003-08-01 | 2005-02-10 | Mochida Pharmaceutical Co., Ltd. | æšçåãããççæ¹èµ·å€ |
Also Published As
Publication number | Publication date |
---|---|
WO2001090382A3 (fr) | 2003-09-12 |
EP1365027A4 (en) | 2005-06-22 |
JPWO2001090382A1 (ja) | 2004-04-30 |
CA2410525A1 (en) | 2001-11-29 |
US20040053249A1 (en) | 2004-03-18 |
EP1365027A2 (en) | 2003-11-26 |
AU2001260633A1 (en) | 2001-12-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6694409B2 (ja) | ïœïœïœïœäžæ¬éåå | |
JP5844158B2 (ja) | äžéäœåœ¢æèåã¿ã³ãã¯è³ª | |
JP3559281B2 (ja) | ïœïŒïŒãªã¬ã³ã | |
JP5031165B2 (ja) | çµã¿æãèåã¿ã³ãã¯è³ªã®ãã€ããŒãããªããŒãã¯ã¢ããããŒåã¯ãã³ã¿ããŒã®ãã€ããŒåã¯ãªãªãŽã㌠| |
EP3298030B1 (en) | Anti-cancer fusion polypeptide | |
JP2865300B2 (ja) | ããïœçŽ°èåºæ¿å åïŒã¬ã»ãã¿ãŒèçœè³ª | |
KR100381788B1 (ko) | ì ê·ëšë°±ì§ë°ê·žì ì¡°ë°©ë²,곚ë€ê³µìŠ,곚ëê°ììŠë°ê³šëì¬ìŽììŠììë°©ëëì¹ë£ì | |
JP4411330B2 (ja) | è «çå£æ»å åé¢é£ãªã¬ã³ã | |
JP6251170B2 (ja) | å®å®ããã¿ã³ãã¯è³ª | |
JPH10502810A (ja) | ïŒ¬ïœ ïœïœâïŒãšåœåãããæ°èŠã®ãµã€ãã«ã€ã³ | |
US20070243584A1 (en) | Tetramerizing polypeptides and methods of use | |
KR101250364B1 (ko) | ì€ì€í ì€íë¡í ê²ëŠ° ë³ìŽì²Ž ëšë°±ì§ | |
EP1019502A2 (en) | Human orphan receptor ntr-1 | |
CA2865288A1 (en) | Tumour necrosis factor receptor fusion proteins and methods of using the same | |
WO1995026985A1 (en) | Modified receptors that continuously signal | |
JP6320973B2 (ja) | 现è掻æ§åå åã®æ®æç©è³ªããã®èª¿è£œæ¹æ³åã³å©çšæ³ | |
WO2007099921A1 (ja) | αãšçµåããããªãããããããã³ãããã³ãŒãããããªãã¯ã¬ãªããã䞊ã³ã«ãã®å©çš | |
CN114591415B (zh) | Glp-1/gcgååäœæ¿åšåå€èœåå ¶èåèçœ | |
WO2001000673A9 (en) | Membrane-associated and secreted proteins and uses thereof | |
WO2001090382A2 (fr) | Proteines de fusion agissant en tant que fas-ligand | |
JP2023538902A (ja) | æäœããããªã¬ã³ãã䜿çšããææåã³æ¹æ³ | |
WO2000069885A2 (en) | Secreted proteins and uses thereof | |
JP2014218510A (ja) | äžéäœåœ¢æèåã¿ã³ãã¯è³ª | |
Sun et al. | Expression, purification, refolding, and characterization of recombinant human soluble-Fas ligand from Escherichia coli | |
JP2839837B2 (ja) | é¡ç²çã³ãããŒåºæ¿å åå容äœã®ãªã¬ã³ãçµåé åèçœè³ªãã³ãŒãããŠããïœïœïœ |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2410525 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001934373 Country of ref document: EP Ref document number: 10296718 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2001934373 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001934373 Country of ref document: EP |